Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    DEN170044
    Device Name
    ClearMate
    Date Cleared
    2019-03-14

    (573 days)

    Product Code
    Regulation Number
    868.5480
    Type
    Direct
    Reference & Predicate Devices
    Predicate For
    N/A
    Why did this record match?
    510k Summary Text (Full-text Search) :

    This device may be labeled for use with breathing circuits made of reservoir bags (21 CFR 868.5320),
    These circuits are constructed of reservoir bags (21 CFR 868.5320, Class I), oxygen cannulas (21 CFR

    Device Description :

    These circuits are constructed of reservoir bags (21 CFR 868.5320, Class I), oxygen cannulas (21 CFR

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    ClearMate™ is intended to be used by emergency department medical professionals as an adjunctive treatment for patients suffering from carbon monoxide poisoning. The use of ClearMate" enables accelerated elimination of carbon monoxide from the body by allowing isocapnic hyperventilation through simulated partial rebreathing.

    Device Description

    This device is intended to induce isocapnic hyperventilation in patients to speed up elimination of carbon monoxide (CO). Isocapnic hyperventilation can be defined as large increases in patient minute volume with minimal changes in arterial partial pressure of carbon dioxide (CO2). This device replaces CO2 levels in the airway, thereby maintaining CO2 levels in the blood that ultimately causes hyperventilation. This pneumatic device initially provides 100% supplemental oxygen (O2) at minute volumes selected based on patient weight. If the patient minute volume demand is more than the preset supplement O2 volume, this device supplies a mixture of 94%/6% (O2/CO2), which maintains CO2 levels in the airway to enable isocapnic breathing by partial simulated rebreathing (of CO2). This device consists of:

    1. The subject of this De Novo, the Control unit ("briefcase"), connects to sources of O2 and CO2 (neither gas is supplied with this device). The unit includes pressure gauges to read the source gas pressures. Internal components control supplemental gas flowrates, gas concentrations, and CO2 diversion away from the gas delivery pathway should O2 pressures be insufficient. This unit weighs about 2 kg and is pneumatically driven (i.e., no electronics).
    2. Two breathing circuits, which are not the subject of this De Novo, can attach to the gas outlet ports of the control unit. These circuits are constructed of reservoir bags (21 CFR 868.5320, Class I), oxygen cannulas (21 CFR 868.5340, Class I), masks (21 CFR 868.5550, cleared under K953107), valves (21 CFR 868.5870, cleared under K142402), resuscitation bags (21 CFR 868.5915, cleared under K912203), and/or tubing (21 CFR 868.5925, cleared under K161420).
    3. Hoses for source gas connections and a device stand for steadying the device, which are a subject of this De Novo.
    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study information for the ClearMate device, based on the provided text:

    Acceptance Criteria and Device Performance

    Acceptance Criteria (Special Controls - 21 CFR 868.5480)Reported Device Performance
    Non-clinical performance testing demonstrates device performs as intended under anticipated conditions of use, including:Verified through bench testing.
    A. Gas concentration accuracy testing for the range of intended concentrations;Control Unit Performance: Ten control units were tested. "Operation of supplemental O2 concentration, blended gas concentrations... All predefined specifications were met."
    B. Airway pressure delivery accuracy testing;Breathing Circuit Performance: "One-way valves (e.g., relief valves, demand valves) were individually tested for minimum pressure responses. Testing validated the worst case range of pressures experienced in the circuits, leakage rate of the circuit... All predefined specifications were met." Control Unit Performance: Not directly mentioned, but implied through the overall performance of the circuits.
    C. Supplemental O2 flowrate accuracy testing;Breathing Circuit Performance: "Supplemental O2 flowrate accuracy specifications. Circuits were tested to facilitate the correct gas concentrations output by the control unit... All predefined specifications were met." Control Unit Performance: "Supplemental O2 flowrate accuracy. All predefined specifications were met."
    D. Alarm testing;Control Unit Performance: Ten control units were tested. "Low O2 pressures (upper and lower limits) that trigger the CO2-driven alarm. CO2 diversion to drive the alarm... All predefined specifications were met."
    E. Use life testing.Use life Performance: Challenged 5 device samples at double the typical maximum breaths per minute and 1.4 times the typical adult tidal volume for 10 hours (simulating 8 patients/year over 5 years). "The results confirm supplemental O2 output and O2/CO2 demand valve operating specifications, which are the components subjected to most repeated use over the use life."
    The patient-contacting components of the device must be demonstrated to be biocompatible.Biocompatibility/Materials: A biological risk assessment was performed in accordance with ISO 10993-1. Components (face mask, adapters, resuscitation bag, leaflet valve) were either previously cleared with similar biocompatibility concerns or tested for dry gas pathway concerns (particulate matter and VOCs). "Based on the submitted testing and evaluations, the applicant has demonstrated device biocompatibility for this intended use."
    Labeling must include:Labeling is required to inform proper use.
    A. Instructions for use;Required.
    B. A precaution that monitoring of capnography is necessary during treatment with nonspontaneously breathing patients; andRequired. "When providing treatment to a non-spontaneously breathing patient using the ClearMate™ non-spontaneous breathing patient circuit, CO2 monitoring equipment for the measurement of expiratory carbon dioxide concentration must be used." and "A precaution that monitoring of capnography is necessary during treatment with nonspontaneously breathing patients."
    C. Use life specification.Required. "The applicant proposed a 5-year use life."

    Study Information

    2. Sample Size Used for the Test Set and Data Provenance:

    The document primarily discusses preclinical (animal and bench) and clinical literature review, rather than a single prospective "test set" for the device itself in the traditional sense of an AI/algorithm.

    • Bench Testing:

      • Breathing Circuit Performance: 10 samples of spontaneously breathing circuits and 10 samples of non-spontaneously breathing circuits (20 samples total).
      • Control Unit Performance: 10 control units.
      • Use Life Performance: 5 device samples.
      • Data Provenance: Retrospective, conducted by the applicant (Thornhill Research, Inc.) presumably in Canada (given the contact address is in Scottsdale, AZ, but the company is Thornhill Research, Inc., which is Canadian). This is inferred as internal testing presented to the FDA.
    • Animal Studies:

      • Fisher JA et al. (1999): Dog model (specific N not provided in the summary). Provenance: Published U.S. study.
      • Krech T et al. (2001): Mechanically ventilated sheep (specific N not provided in the summary). Provenance: Published U.S. study.
    • Human Clinical Literature Review (considered as evidence of effectiveness):

      • Anand et al. (2017): 13 healthy volunteers (chronic smokers). Provenance: Published study (journal name "PLOS One" suggests an international publication, DOI:10.1371/journal.pone.0170621).
      • Rucker et al. (2002): 14 healthy volunteers. Provenance: Published U.S. study.
      • Takeuchi et al. (2000): Healthy human volunteers (specific N not provided in the summary). Provenance: Published U.S. study.
      • Katznelson et al. (2008): Specific N not provided in the summary (anesthetic agents study). Provenance: Published study.
      • Katznelson et al. (2011): 44 obese elective surgical patients (anesthetic agents study). Provenance: Published study.
      • Wu et al. (2015) - external study, not used for efficacy but for safety: 319 patients in treatment group, 320 in control group. Provenance: Chinese study, published in "Chinese Journal of Clinicians."

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications:

    This device is not an AI/algorithm requiring expert-established ground truth for a test set in the diagnostic sense. The "ground truth" for its performance is derived from:

    • Bench Testing: Engineering specifications and physical measurements. Experts involved would be engineering and quality control personnel. Their specific qualifications are not detailed, but they would be presumed to be qualified engineers/technicians.
    • Animal Studies: Scientific observation and measurement by researchers/veterinarians.
    • Human Clinical Studies: Clinical endpoints (e.g., COHb levels, elimination half-life, cerebral blood flow) measured by medical professionals and researchers. The peer-review process for these published studies implicitly involves expert clinicians and scientists.

    4. Adjudication Method for the Test Set:

    Not applicable, as this is not an AI/diagnostic algorithm using expert review for a "test set." For the literature review, the FDA's internal review team served as the adjudicators of the existing scientific evidence.

    5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done:

    No, an MRMC comparative effectiveness study, in the context of human reader performance with/without AI assistance, was not performed. The device is a physical therapeutic device, not a diagnostic AI system intended to assist human readers.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done:

    Yes, the device itself is the "standalone" component. Its performance was evaluated independently through bench testing (as detailed in item #2) and animal studies. The human clinical studies also assess the device's effect on physiological markers when used therapeutically.

    7. The Type of Ground Truth Used:

    • Bench Testing: Device specifications, physical properties, engineering standards, and direct measurement of gas concentrations, flow rates, and pressures.
    • Animal Studies: Physiological measurements (e.g., COHb levels, cardiac output, oxygen delivery) directly measured from the animal subjects.
    • Human Clinical Studies (for effectiveness): Physiological measurements (e.g., COHb levels, elimination half-life, cerebral blood flow) obtained from human volunteers or patients using established medical measurement techniques.
    • Human Clinical Study (Wu et al. for safety, but with limitations on efficacy): Clinical outcomes adjudicated by medical personnel based on consciousness, continence, disappearance of CO poisoning signs, EEG findings, and BI (Barthel Index) scores.

    8. The Sample Size for the Training Set:

    Not applicable. This is a physical medical device, not an AI model requiring a training set in the machine learning sense. The device's design is based on scientific principles of isocapnic hyperventilation, not data training.

    9. How the Ground Truth for the Training Set was Established:

    Not applicable (as above). The design and performance targets for the ClearMate device are based on established physiological principles and engineering requirements, not on a "ground truth" derived from a training dataset for an AI algorithm.

    Ask a Question

    Ask a specific question about this device

    K Number
    K181424
    Device Name
    PeDIA
    Manufacturer
    Date Cleared
    2018-09-25

    (117 days)

    Product Code
    Regulation Number
    868.5320
    Reference & Predicate Devices
    Predicate For
    N/A
    Why did this record match?
    510k Summary Text (Full-text Search) :

    Trade/Device Name: Pediatric Device for Induction of Anesthesia (PeDIA) Regulation Number: 21 CFR 868.5320
    Reservoir bag Classification Name: Bag Device Class: I Panel: Anesthesiology Product Code: BTC Regulation: 868.5320
    | Regulation Number | 868.5320
    | 868.5320

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The pediatric device for induction of anesthesia (PeDIA) is an alternative to a face mask for the inhalation induction of anesthesia, and is intended for the delivery of nitrous and/or anesthetic gases to children age three years and older. It is intended to be used prior to IV insertion, LMA/endotracheal intubation, and/or conversion to a standard mask induction.

    Device Description

    The Pediatric Device for Induction of Anesthesia (PeDIA) is a single-use, disposable, mask-free anesthetic delivery system and method used for children 3 years and older. The balloon is a standard, legally marketed reservoir bag that is modified by the addition of a whistle at the opposite end of the connector (which is a closed end on standard balloons). This balloon is used in place of the initial application of anesthesia gasses. Once the child is sedated the product is removed and replaced with a standard pediatric mask for the duration of anesthesia.

    AI/ML Overview

    When analyzing the provided text for acceptance criteria and a study proving device performance, it's important to note that this FDA 510(k) clearance document is for a Class I medical device (a reservoir bag with a modification), not typically a device that requires extensive clinical studies with human participants to demonstrate performance or to assess diagnostic accuracy in the way that, for example, an AI-powered diagnostic imaging device would.

    The "performance data" discussed here focuses on engineering, biocompatibility, and regulatory compliance rather than diagnostic performance metrics like sensitivity, specificity, or reader improvement.

    Therefore, many of the requested points related to AI/MRMC studies, expert ground truth, and training data will not be present in this document, as they are not applicable to the type of device and regulatory pathway involved.

    Here's a breakdown based on the provided text:

    1. A table of acceptance criteria and the reported device performance

    The document doesn't provide a direct table of acceptance criteria with corresponding performance numbers in the way one might expect for a diagnostic AI device. Instead, it describes general compliance and testing outcomes.

    Acceptance Criteria CategoryReported Device Performance (as inferred from the text)
    Shelf-LifeDevice is non-sterile and has no restriction on shelf-life.
    BiocompatibilitySuccessfully passed testing per FDA guidance (ISO 10993-1, June 16, 2016) for: - Cytotoxicity - Sensitization - Irritation - Acute Toxicity - Pyrogenicity
    Risk ManagementAll identified risks were reduced to acceptable levels by mitigation (design, labels, biocompatibility). All residual risks post-mitigation were deemed acceptable.
    Standard ComplianceConfirmed compliance with: - ISO 5362 (Anesthetic Reservoir bags) - ISO 5356-1 (Anesthetic and respiratory equipment – conical connectors – Part 1: Cones and Sockets). This includes requirements for connectivity, capacity, leakage, disconnection, resistance to pressure, and design.
    Verification TestingAll requirements (other than those addressed by standardized testing) were confirmed against specifications, labeling, and instructional requirements via a pre-approved protocol.
    Overall Conclusion"Tests were successfully performed and all acceptance criteria were met, thus confirming that the PeDIA device satisfactorily meets requirements. There were no different questions of safety and effectiveness identified..."

    2. Sample size used for the test set and the data provenance

    • Sample Size: Not specified in terms of clinical study sample size. The tests appear to be laboratory and bench testing on the device prototypes/samples. No patient "test set" in the diagnostic sense is mentioned.
    • Data Provenance: Not applicable in the context of diagnostic data. The "data" refers to engineering test results and biocompatibility assays.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    • Not applicable. This device does not generate diagnostic outputs requiring expert interpretation for ground truth. The "ground truth" here is compliance with engineering standards and safety/biocompatibility profiles.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    • Not applicable. There are no diagnostic interpretations to adjudicate.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    • No. This is not an AI/diagnostic device, and no MRMC study was performed or required.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    • No. Not an AI device.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

    • The "ground truth" for this device's performance is adherence to established international standards (ISO 5362, ISO 5356-1) and FDA guidance for biocompatibility (ISO 10993-1), along with internal design specifications. There is no clinical "ground truth" in the diagnostic sense.

    8. The sample size for the training set

    • Not applicable. This is not an AI device that requires a "training set."

    9. How the ground truth for the training set was established

    • Not applicable.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1